Drug Trial Radar · NCT03033745
Safety and Tolerability of Higher Infusion Parameters of IgPro20 (Hizentra) in Subjects With Primary Immunodeficiency (PID)
Last checked: Nov 19, 2026Latest source record: Mar 25, 2020 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
49
Actual
Start
Feb 1, 2017
Primary completion
Dec 14, 2018
Study completion Dec 14, 2018
Sponsor
- Lead sponsor
- CSL BehringIndustry
- Sponsor type
- Industry
- First posted
- Jan 27, 2017
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 2 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This multicenter, open-label, parallel-arm, non-randomized study is designed to evaluate safety and tolerability of higher infusion parameters of IgPro20 in subjects with primary immunodeficiency (PID). A total of 45 subjects (including at least 14 \[30%\] pediatric subjects ≤ 17 years of age and at least 9 \[20%\] obese subjects with body mass index \[BMI\] of ≥30 kg/m2) with confirmed PID will be evaluated in the study. The study will include three cohorts of 15 subjects each as follows: i) Pump-Assisted Volume Cohort (weekly infusions), volume per injection site of 25 mL up to 50 mL, ii) Pump Assisted Flow Rate Cohort (weekly infusions), flow rate per injection site of 25 mL/hour up to 100 mL/hour, iii) Manual Push Flow Rate Cohort (2 to 7 infusions per week), flow rate per injection site of 25 to 30 mL/hour up to 120 mL/hour (equivalent of approximately 0.5 mL/minute up to 2 mL/minute). Each cohort will test 3 infusion parameter levels (4 for the pump-assisted flow rate cohort), repeated at least 4 times over a duration of 12 weeks (16 weeks for the flow rate cohort). After 4 infusion weeks at each level, qualifying subjects (responders) will switch to the next infusion parameter level (eg, from 25 to 50 mL/h). During the study, the weekly dose will remain unchanged (as prescribed by treating physician, usually within 100-200 mg/kg per week range); only the respective infusion parameter under evaluation will change.
Conditions
- Primary Immunodeficiency
Interventions
IgPro20Drug
A liquid formulation of normal human IgG at a concentration of 20% administered as a subcutaneous infusion at a dose prescribed by subject's physician prior to study entry.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of RespondersTime frame: At the end of 4 weeks for each planned infusion parameter
Locations
12 sites in 2 countries. Site status is shown where the registry gives one.
Clinical Research Center of Alabama
Birmingham, Alabama
Research Solutions of Arizona
Litchfield Park, Arizona
University of Southern Florida
St. Petersburg, Florida
Georgia Pollens Clinical Research Centers
Albany, Georgia
Long Island Jewish Medical Center
Great Neck, New York
Icahn Medical Institute
New York, New York
Center for Clinical Research Rochester General Hospital
Rochester, New York
Levine Children's Hospital
Charlotte, North Carolina
Duke University School of Medicine
Durham, North Carolina
Medical College of Wisconsin
Milwaukee, Wisconsin
The Ottawa Hospital
Ottawa, Ontario, Canada
McGill University
Montreal, Quebec, Canada
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.